Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

This trial is studying a new drug called inotuzumab ozogamicin combined with chemotherapy to treat a type of blood cancer called acute lymphoblastic leukemia (ALL) in older or less healthy adults. **You may be eligible if...** - You are 60 years of age or older with a newly diagnosed ALL blood cancer (pre-B type), and have received little or no prior treatment - You are 18–59 years old with the same type of ALL but are considered unfit for standard intensive chemotherapy due to health conditions such as heart problems, lung problems, kidney problems, liver problems, or a general low energy/fitness level (ECOG score of 2 or higher) - You are 60 or older with health conditions that make you unable to tolerate aggressive chemotherapy - You have reasonable liver and kidney function - You are willing and able to give informed consent **You may NOT be eligible if...** - You have active, uncontrolled infection or serious illness not related to the cancer - Your liver or kidney function is severely impaired beyond study limits - You are pregnant or breastfeeding - You have a prior history of certain serious heart conditions (like QT prolongation) - You are unwilling to provide consent Talk to your doctor to see if this trial is right for you.